GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H1 2017

  • ID: 4311835
  • Report
  • 54 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Mirati Therapeutics Inc
  • Nuevolution AB
  • PeptiDream Inc
  • Tosk Inc
  • MORE
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H1 2017

Summary:

According to the recently published report 'GTPase KRas - Pipeline Review, H1 2017'; GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) pipeline Target constitutes close to 23 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes.

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - KRAS is a GTPase encoded by the KRAS gene. It plays an important role in the regulation of cell proliferation, promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner.

The report 'GTPase KRas - Pipeline Review, H1 2017' outlays comprehensive information on the GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviewsalso reviews key players involved in GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical and Discovery stages are 9 and 9 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Lung Cancer, Pancreatic Cancer, Colon Cancer, Colorectal Cancer, Small-Cell Lung Cancer and Solid Tumor.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)
  • The report reviews GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Mirati Therapeutics Inc
  • Nuevolution AB
  • PeptiDream Inc
  • Tosk Inc
  • MORE
  1. Introduction
  2. GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Overview
  3. GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Therapeutics Assessment
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Companies Involved in Therapeutics Development
  14. AstraZeneca Plc
  15. Aurigene Discovery Technologies Ltd
  16. Boehringer Ingelheim GmbH
  17. Critical Outcome Technologies Inc
  18. Horizon Discovery Group Plc
  19. Mirati Therapeutics Inc
  20. Nuevolution AB
  21. PeptiDream Inc
  22. Takeda Pharmaceutical Company Ltd
  23. Tosk Inc
  24. Warp Drive Bio Inc
  25. GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Drug Profiles
  26. Antibody to Inhibit KRAS for Oncology - Drug Profile
  27. Product Description
  28. Mechanism Of Action
  29. R&D Progress
  30. ARS-853 - Drug Profile
  31. Product Description
  32. Mechanism Of Action
  33. R&D Progress
  34. AZD-4785 - Drug Profile
  35. Product Description
  36. Mechanism Of Action
  37. R&D Progress
  38. COTI-219 - Drug Profile
  39. Product Description
  40. Mechanism Of Action
  41. R&D Progress
  42. HD-001 - Drug Profile
  43. Product Description
  44. Mechanism Of Action
  45. R&D Progress
  46. KRpep-2d - Drug Profile
  47. Product Description
  48. Mechanism Of Action
  49. R&D Progress
  50. MM-41 - Drug Profile
  51. Product Description
  52. Mechanism Of Action
  53. R&D Progress
  54. Monoclonal Antibody to Inhibit KRAS for Pancreatic Cancer - Drug Profile
  55. Product Description
  56. Mechanism Of Action
  57. R&D Progress
  58. Oligonucleotide to Inhibit KRAS for Lung Cancer and Colon Cancer - Drug Profile
  59. Product Description
  60. Mechanism Of Action
  61. R&D Progress
  62. Small Molecule to Inhibit K-RAS for Non-Small Cell Lung Cancer - Drug Profile
  63. Product Description
  64. Mechanism Of Action
  65. R&D Progress
  66. Small Molecule to Inhibit KRAS for Oncology - Drug Profile
  67. Product Description
  68. Mechanism Of Action
  69. R&D Progress
  70. Small Molecule to Inhibit KRAS for Oncology - Drug Profile
  71. Product Description
  72. Mechanism Of Action
  73. R&D Progress
  74. Small Molecules 1 to Inhibit K-Ras for Oncology - Drug Profile
  75. Product Description
  76. Mechanism Of Action
  77. R&D Progress
  78. Small Molecules 2 to Inhibit K-Ras for Oncology - Drug Profile
  79. Product Description
  80. Mechanism Of Action
  81. R&D Progress
  82. Small Molecules 3 to Inhibit K-Ras for Oncology - Drug Profile
  83. Product Description
  84. Mechanism Of Action
  85. R&D Progress
  86. Small Molecules to Inhibit K Ras for Oncology - Drug Profile
  87. Product Description
  88. Mechanism Of Action
  89. R&D Progress
  90. Small Molecules to Inhibit K-Ras for Oncology - Drug Profile
  91. Product Description
  92. Mechanism Of Action
  93. R&D Progress
  94. Small Molecules to Inhibit KRAS for Non-Small Cell Lung Cancer - Drug Profile
  95. Product Description
  96. Mechanism Of Action
  97. R&D Progress
  98. Small Molecules to Inhibit KRAS for Oncology - Drug Profile
  99. Product Description
  100. Mechanism Of Action
  101. R&D Progress
  102. Small Molecules to Inhibit KRAS2B for Oncology - Drug Profile
  103. Product Description
  104. Mechanism Of Action
  105. R&D Progress
  106. SML-8731 - Drug Profile
  107. Product Description
  108. Mechanism Of Action
  109. R&D Progress
  110. Synthetic Peptides to Inhibit KRAS for Oncology - Drug Profile
  111. Product Description
  112. Mechanism Of Action
  113. R&D Progress
  114. Vaccine to Target K-RAS for Lung Cancer - Drug Profile
  115. Product Description
  116. Mechanism Of Action
  117. R&D Progress
  118. GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Dormant Products
  119. GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Product Development Milestones
  120. Featured News & Press Releases
  121. Dec 16, 2016: Ionis Earns $28 Million from AstraZeneca for a New Drug to Treat Cancer
  122. Oct 11, 2016: Critical Outcome Technologies Announces Next Clinical Candidate, COTI-219, Targeting KRAS
  123. Jul 29, 2014: Researchers Identify Irreversible Inhibitor for KRAS Gene Mutation
  124. May 08, 2013: Sentinel Oncology Achieves Milestone In Horizon Discovery Agreement
  125. Appendix
  126. Methodology
  127. Coverage
  128. Secondary Research
  129. Primary Research
  130. Expert Panel Validation
  131. Contact Us
  132. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indication, H1
  4. Number of Products under Development by Companies, H1
  5. Products under Development by Companies, H1
  6. Number of Products under Investigation by Universities/Institutes, H1
  7. Products under Investigation by Universities/Institutes, H1
  8. Number of Products by Stage and Mechanism of Actions, H1
  9. Number of Products by Stage and Route of Administration, H1
  10. Number of Products by Stage and Molecule Type, H1
  11. Pipeline by AstraZeneca Plc, H1
  12. Pipeline by Aurigene Discovery Technologies Ltd, H1
  13. Pipeline by Boehringer Ingelheim GmbH, H1
  14. Pipeline by Critical Outcome Technologies Inc, H1
  15. Pipeline by Horizon Discovery Group Plc, H1
  16. Pipeline by Mirati Therapeutics Inc, H1
  17. Pipeline by Nuevolution AB, H1
  18. Pipeline by PeptiDream Inc, H1
  19. Pipeline by Takeda Pharmaceutical Company Ltd, H1
  20. Pipeline by Tosk Inc, H1
  21. Pipeline by Warp Drive Bio Inc, H1
  22. Dormant Projects, H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Indications, H1
  3. Number of Products by Stage and Mechanism of Actions, H1
  4. Number of Products by Routes of Administration, H1
  5. Number of Products by Stage and Routes of Administration, H1
  6. Number of Products by Molecule Types, H1
  7. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AstraZeneca Plc
  • Aurigene Discovery Technologies Ltd
  • Boehringer Ingelheim GmbH
  • Critical Outcome Technologies Inc
  • Horizon Discovery Group Plc
  • Mirati Therapeutics Inc
  • Nuevolution AB
  • PeptiDream Inc
  • Takeda Pharmaceutical Company Ltd
  • Tosk Inc
  • Warp Drive Bio Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll